IMMU Immunomedics, Inc.

5.34
+0.23  (4.4%)
Previous Close 5.11
Open 5.10
Price To book 0.00
Market Cap 566.46M
Shares 106,079,000
Volume 5,696,541
Short Ratio 10.09
Av. Daily Volume 2,952,980

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated early 2017. BLA filing due mid-2017.
SACTUZUMAB GOVITECAN (IMMU-132)
Cancer - metastatic triple-negative breast cancer
Phase 2 update provided at ASCO June 2016. Ongoing through 2017.
SACITUZUMAB GOVITECAN
Non-small cell lung cancer (NSCLC)
Phase 2 interim data presented April 2016
Labetuzumab govitecan
Metastatic colorectal cancer (mCRC)
Phase 3 trial terminated due to poor efficacy
Clivatuzumab tetraxetan
Cancer - Pancreatic
Endpoints not met July 2015
Epratuzumab (EMBODY 1 and 2)
Lupus

Latest News

  1. IMMUNOMEDICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  2. 8:16 am Immunomedics files a federal lawsuit and a motion seeking injunctive relief against venBio Select Advisor and venBio's four director candidates
  3. Immunomedics Files Federal Lawsuit Against venBio for Continuing Material Violations of the Federal Securities Laws
  4. IMMUNOMEDICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  5. Immunomedics Presents Updated Results With Sacituzumab Govitecan (IMMU-132) in Heavily-Pretreated Patients With Metastatic Urothelial Cancer
  6. VenBio Tries to Block Immunomedics Cancer Deal
  7. IMMUNOMEDICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti
  8. IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  9. Immunomedics Sends Letter to Stockholders Highlighting Value Creating Global Licensing Agreement, Underscoring Fulfillment of Promise to Stockholders
  10. IMMUNOMEDICS INC Financials
  11. Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q2, 2017 By the Numbers : February 15, 2017
  12. Seattle Genetics signs $2B licensing deal with Immunomedics for cancer drug
  13. Immunomedics Comments on Baseless venBio Lawsuit
  14. Activist Investor to Block Partnership of Immunomedics and Seattle Genetics
  15. venBio Takes Steps to Protect Rights of Immunomedics Stockholders
  16. Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics
  17. Here’s Our Take On The Immunomedics, Inc. (IMMU) Deal
  18. Blog Coverage Immunomedics Announces a $2 Billion Cancer Deal with Seattle Genetics
  19. Edited Transcript of IMMU earnings conference call or presentation 10-Feb-17 1:00pm GMT
  20. Will Seattle Genetics' Deal With Immunomedics Get Scuttled?